FDA Highlights Post-Approval Cardiovascular and Gastrointestinal Data for Semaglutide

FDA Highlights Post-Approval Cardiovascular and Gastrointestinal Data for Semaglutide

The FDA issued an updated safety communication on extended follow-up from the SELECT trial for semaglutide products [2]. The agency reported that the trial continued to show cardiovascular benefits in adults with overweight or obesity and established cardiovascular disease without diabetes, with no new major safety signals identified during additional observation [2]. Data from the primary analysis had shown a 20% reduction in major adverse cardiovascular events (MACE) [1].

The communication also addressed gastrointestinal events and neuropsychiatric outcomes, stating that trial data do not support a causal link to suicidal ideation or behavior [2].

What this means

The findings indicate that the cardiovascular risk reduction observed in the SELECT trial persisted in extended follow-up beyond the primary analysis period. Gastrointestinal disorders remained the most frequently reported adverse events and stayed consistent with the approved product labeling. The available evidence from this trial in the specified population does not establish an association with increased risk of suicidal ideation.

SELECT Trial Cardiovascular Outcomes

The SELECT trial (NCT03574597) showed that semaglutide 2.4 mg weekly reduced MACE by 20% compared with placebo (HR 0.80; 95% CI 0.72-0.90) [1]. Median follow-up in the primary analysis was 39.8 months, with additional observational data collected afterward [1][3].

Extended Follow-Up Safety Profile

The FDA stated on September 20, 2024, that no new safety signals were identified in the SELECT trial extended follow-up [2]. Gastrointestinal disorders remained the most common adverse events, and the overall safety profile was consistent with approved labeling [2].

Neuropsychiatric Safety Assessment

FDA review of SELECT trial neuropsychiatric data found no causal association between semaglutide and suicidal ideation or behavior [2]. This assessment aligns with the trial’s protocol-specified monitoring and prior regulatory reviews of GLP-1 receptor agonists [2].

Trial Registry and Data Timeline

The ClinicalTrials.gov record confirms primary completion of the SELECT trial occurred in June 2023, with additional follow-up data subsequently submitted to the FDA [3]. The registry entry documents ongoing collection and analysis beyond the initial endpoint [3].

Limitations

SELECT excluded patients with severe psychiatric illness or recent history of suicidality, limiting extrapolation to those populations [2]. The observational follow-up component is non-randomized and subject to confounding. Rare events with long latency may require even larger or longer post-marketing studies for definitive assessment [2].